| Ytd | -18.15% | |
| 1y | 92.19% |
| Open | 32.85 | Prev Close | 32.91 | Low | 32.01 | High | 32.99 | Mkt Cap | 86.13M |
| Vol | 25.28K | Avg Vol | 57.31K | EPS | -0.93 | P/E | -35.39 | Forward P/E | -42.03 |
| Beta | 0.25 | Short Ratio | 1.50 | Inst. Own | 14.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 33.79 | 200-d Avg | 32.91 | 1yr Est | 35.00 |
VTVT News
Recent analyst rating changes, top names such as PPG, SAH, ISRG, MMM, OKE, GLDG, ABT, NFLX, TSCO, an
Top Wall Street analysts changed their outlook on top names. See all changes, including upgrades and
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the pric
HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
If you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therape
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet e
HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stag
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stag
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stoc
HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-st
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stoc
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vT
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-st
Wall Street analysts changed outlook on top names. See ratings page for upgrades, downgrades, and in
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to
I think VTVT is a largely underfollowed T1D catalyst story, with Phase 3 CATT1 cadisegliatin topline
vTv Therapeutics Inc. (NASDAQ: VTVT - Get Free Report) saw a large growth in short interest during t
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-sta
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclus
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D Trial
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in vT
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
On Wednesday, 807 companies reached new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
Stocks That Hit 52-Week Highs On Monday